TDP-43 pathology is associated with increased tau burdens and seeding
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Background: Most Alzheimer’s Disease (AD) cases also exhibit limbic predominant age-related TDP-43 encephalopathy neuropathological changes (LATE-NC), besides amyloid-β plaques and neurofibrillary tangles (NFTs) containing hyperphosphorylated tau (p-tau). LATE-NC is characterized by cytoplasmic aggregates positive for pathological TDP-43 and is associated with more severe clinical outcomes in AD, compared to AD cases lacking TDP-43 pathology TDP-43: AD(LATE-NC-). Accumulating evidence suggests that TDP-43 and p-tau interact and exhibit pathological synergy during AD pathogenesis. However, it is not yet fully understood how the presence of TDP-43 affects p-tau aggregation in symptomatic AD. Methods: In this study, we investigated the impact of TDP-43 proteinopathy on p-tau pathology with different approaches: histologically, in a human post-mortem cohort (n = 98), as well as functionally using a tau biosensor cell line and TDP-43 A315T transgenic mice. Results: We found that AD cases with comorbid LATE-NC, AD(LATE-NC+), have increased burdens of pretangles and/or NFTs as well as increased brain levels of p-tau199, compared to AD(LATE-NC-) cases and controls. The burden of TDP-43 pathology was also correlated with the Braak NFT stages. A tau biosensor cell line treated with sarkosyl-insoluble, brain-derived homogenates from AD(LATE-NC+) cases displayed exacerbated p-tau seeding, compared to control and AD(LATE-NC-)-treated cells. Consistently, TDP-43 A315T mice injected with AD(LATE-NC+)-derived extracts also exhibited a more severe hippocampal seeding, compared to the remaining experimental groups, albeit no TDP-43 aggregation was observed. Conclusions: Our findings extend the current knowledge by supporting a functional synergy between TDP-43 and p-tau. We further demonstrate that TDP-43 pathology worsens p-tau aggregation in an indirect manner and increases its seeding potential, probably by increasing p-tau levels. This may ultimately contribute to tau-driven neurotoxicity and cell death. Because most AD cases present with comorbid LATE-NC, this study has an impact on the understanding of TDP-43 and tau pathogenesis in AD and LATE, which account for the majority of dementia cases worldwide. Moreover, it highlights the need for the development of a biomarker that detects TDP-43 during life, in order to properly stratify AD and LATE patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phases of Aβ-deposition in the human brain and its relevance for the development of AD
Thal, D. R., Rüb, U., Orantes, M., & Braak, H. (2002) · Neurology · doi:10.1212/wnl.58.12.1791 · Cited by 3,490 · cited 1×
“were assessed as described previously, based on anti-Aβ17-24 stained brain sections [32].”
MethodSelf-citationBraak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H., & Del Tredici, K. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0127-z · Cited by 3,172 · cited 1×
“Braak stages for NFTs spread in the brain were determined as previously described based on anti-p-tau202/205 immunostained sections [33].”
MethodHyman, B. T., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Carrillo, M. C., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., et al. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.10.007 · Cited by 3,092 · cited 1×
“The neuropathological diagnosis of ADNC was performed as published by the National Institute of Aging and Alzheimer Association working group (NIA-AA criteria) [34].”
MethodSelf-citationStages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years
Braak, H., Thal, D. R., Ghebremedhin, E., & Del Tredici, K. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318232a379 · Cited by 2,194 · cited 1×
“Additionally, the criteria for selecting controls included the absence of Aβ plaques (Aβ phase 0), excluding a high number of cases with advanced age [75].”
BackgroundSelf-citationLimbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report
Nelson, P. T., Dickson, D. W., Trojanowski, J. Q., Jack, C. R., Boyle, P. A., Arfanakis, K., Rademakers, R., Alafuzoff, I., Attems, J., Brayne, C., et al. (2019) · Brain · doi:10.1093/brain/awz099 · Cited by 1,547
Stages of pTDP‐43 pathology in amyotrophic lateral sclerosis
Brettschneider, J., Del Tredici, K., Toledo, J. B., Robinson, J. L., Irwin, D. J., Grossman, M., Suh, E., Van Deerlin, V. M., Wood, E. M., Baek, Y., et al. (2013) · Annals of Neurology · doi:10.1002/ana.23937 · Cited by 1,065
Murray, M. E., Graff-Radford, N. R., Ross, O. A., Petersen, R. C., Duara, R., & Dickson, D. W. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70156-9 · Cited by 972 · cited 1×
“between tau and TDP-43 may be more relevant in the limbic-predominant and typical subtypes of AD [60], as TDP-43 aggregates rarely spread to the cortical areas in AD [5, 25].”
BackgroundTDP‐43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease
Amador‐Ortiz, C., Lin, W., Ahmed, Z., Personett, D., Davies, P., Duara, R., Graff‐Radford, N. R., Hutton, M. L., & Dickson, D. W. (2007) · Annals of Neurology · doi:10.1002/ana.21154 · Cited by 916 · cited 2×
“5), this study has an impact in the understanding of TDP-43 pathogenesis in AD and LATE, which account for the majority of dementia cases worldwide [2, 6, 80].”
BackgroundRobinson, J. L., Lee, E. B., Xie, S. X., Rennert, L., Suh, E., Bredenberg, C., Caswell, C., Van Deerlin, V. M., Yan, N., Yousef, A., et al. (2018) · Brain · doi:10.1093/brain/awy146 · Cited by 729
Proteopathic tau seeding predicts tauopathy in vivo
Holmes, B. B., Furman, J. L., Mahan, T. E., Yamasaki, T. R., Mirbaha, H., Eades, W. C., Belaygorod, L., Cairns, N. J., Holtzman, D. M., & Diamond, M. I. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1411649111 · Cited by 696 · cited 3×
“tau seeding in a tau biosensor cell line In order to functionally address the hypothesis that TDP43 aggravates p-tau pathogenesis, we performed seeding assays using a previously established tau biosensor cell line [26].”
BackgroundMethod
Cited by
Cholerton, B., Godrich, D., Pasteris, J., Rivero, J., Martin, E. R., Kunkle, B. W., Naj, A. C., Hamilton-Nelson, K. L., Wang, H., Lee, W.-P., et al. (2026) · PLOS Genetics · doi:10.1371/journal.pgen.1012170 · Cited by 1
Mutation-specific neuropathologic signatures in MAPT-associated frontotemporal lobar degeneration
Bogdani, M., Jadhav, V. S., Kraemer, B. C., Grabowski, T. J., Jayadev, S., Domoto-Reilly, K., Liachko, N. F., Bird, T. D., Dirk Keene, C., & Latimer, C. S. (2026) · Acta Neuropathologica · doi:10.1007/s00401-026-03047-w · Cited by 1
Metadata
- Authors
- Tomé, S. O., Tsaka, G., Ronisz, A., Ospitalieri, S., Gawor, K., Gomes, L. A., Otto, M., von Arnim, C. A. F., Van Damme, P., Van Den Bosch, L., Ghebremedhin, E., Laureyssen, C., Sleegers, K., Vandenberghe, R., Rousseau, F., Schymkowitz, J., & Thal, D. R.
- Venue
- Molecular Neurodegeneration
- Published
- 2023-09-30
- Volume
- 18
- Issue
- 1
- Pages
- 71-71
- ISSN
- 1750-1326 (ISSN-L)
- OpenAlex
- W4387209649
- Cited by
- 66
- References
- 21
- FWCI
- 9.56
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: TDP-43 pathology is associated with increased tau burdens and seeding. https://app.cochat.ai/papers/10.1186/s13024-023-00653-0
- The paper
- Tomé, S. O., Tsaka, G., Ronisz, A., Ospitalieri, S., Gawor, K., Gomes, L. A., Otto, M., von Arnim, C. A. F., Van Damme, P., Van Den Bosch, L., Ghebremedhin, E., Laureyssen, C., Sleegers, K., Vandenberghe, R., Rousseau, F., Schymkowitz, J., & Thal, D. R. (2023). TDP-43 pathology is associated with increased tau burdens and seeding. Molecular Neurodegeneration. https://doi.org/10.1186/s13024-023-00653-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.